Big Money Sentiment increased to 1.4 in Q2 2018. It has change of 0.41, from 2018Q1’s 0.99. The ratio improved due to bluebird bio, Inc. positioning: 36 sold and 69 reduced. 49 funds took positions and 98 increased positions. Investors holded 51.45 million in 2018Q1 but now own 51.83 million shares or 0.73% more.
Kbc Grp Nv stated it has 0.02% in bluebird bio, Inc. (NASDAQ:BLUE). Geode Capital Mgmt Ltd Liability holds 0.02% of its capital in bluebird bio, Inc. (NASDAQ:BLUE) for 481,029 shs. Royal Bancshares Of Canada owns 0% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 61,054 shs. Mirae Asset Invests Ltd holds 0.01% of its capital in bluebird bio, Inc. (NASDAQ:BLUE) for 3,608 shs. Private Advisor Group Inc Lc owns 0.01% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 2,398 shs. Los Angeles Capital Mgmt & Equity reported 135,086 shs or 0.12% of all its holdings. Fairfield Bush And Com accumulated 2,000 shs or 0.09% of the stock. 35,087 were reported by Van Eck Associate. Parallax Volatility Advisers Lp invested in 0% or 1,525 shs. Bokf Na invested in 0.09% or 21,625 shs. Raymond James Fin Services Advsr holds 0% in bluebird bio, Inc. (NASDAQ:BLUE) or 2,253 shs. Invesco Limited stated it has 139,266 shs or 0.01% of all its holdings. Gp One Trading Ltd Partnership holds 54,929 shs or 0.07% of its capital. Dimensional Fund Advsrs L P has 0.01% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 131,520 shs. Rothschild Investment Corp Il invested in 0.13% or 6,540 shs.
bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage
In total 9 analysts cover Bluebird Bio (NASDAQ:BLUE). “Buy” rating has 6, “Sell” are 1, while 2 are “Hold”. (NASDAQ:BLUE) has 67% bullish analysts. 12 are the (NASDAQ:BLUE)’s ratings reports on Nov 10, 2018 according to StockzIntelligence Inc. In Monday, November 5 report Wedbush maintained the stock with “Outperform” rating. In Monday, November 5 report Janney Capital upgraded the stock to “Buy” rating. The company rating was maintained by BTIG Research on Friday, June 1. On Thursday, May 31 the stock has “Overweight” rating by PiperJaffray. On Tuesday, June 19 the firm has “Outperform” rating given by Evercore. On Friday, June 15 the firm has “Buy” rating given by BTIG Research. On Sunday, June 3 Cantor Fitzgerald maintained bluebird bio, Inc. (NASDAQ:BLUE) rating. Cantor Fitzgerald has “Sell” rating and $12200 target. The company rating was maintained by Morgan Stanley on Monday, November 5. On Monday, October 15 Morgan Stanley maintained the shares of BLUE in report with “Equal-Weight” rating. In Monday, June 4 report Oppenheimer maintained the stock with “Hold” rating. Listed here are bluebird bio, Inc. (NASDAQ:BLUE) PTs and latest ratings.
05/11/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $186 New Target: $185 Maintain
05/11/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $204 New Target: $166 Maintain
05/11/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $170 New Target: $170 Upgrade
15/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $190 New Target: $186 Maintain
15/06/2018 Broker: BTIG Research Rating: Buy New Target: $250.0000 Maintain
15/06/2018 Broker: Oppenheimer Rating: Hold Maintain
19/06/2018 Broker: Evercore Old Rating: In-Line New Rating: Outperform Old Target: $175 New Target: $230 Upgrade
04/06/2018 Broker: Oppenheimer Rating: Hold Maintain
03/06/2018 Broker: Cantor Fitzgerald Rating: Sell New Target: $122.0000 Maintain
01/06/2018 Broker: BTIG Research Rating: Buy New Target: $250.0000 Maintain
BLUE is hitting $126.33 during the last trading session, after decreased 4.60%.Currently bluebird bio, Inc. is uptrending after 15.36% change in last November 10, 2017. BLUE has also 632,558 shares volume. The stock underperformed the S&P 500 by 0.26%.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.The firm is worth $6.91 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease.Currently it has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.
For more bluebird bio, Inc. (NASDAQ:BLUE) news brought out briefly go to: Fool.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Fool.com. The titles are as follows: “3 Top Biotech Stocks to Buy in November” brought out on November 07, 2018, “bluebird bio, Inc. (BLUE) CEO Nick Leschly on Q3 2018 Results – Earnings Call Transcript” on November 02, 2018, “3 Cancer Stocks to Watch in December” with a publish date: November 07, 2018, “Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation” and the last “Here’s Why bluebird bio Jumped 13.5% Today” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.